Natural history and determinants of clinical severity of sickle cell disease
- PMID: 9371979
- DOI: 10.1097/00062752-199502020-00001
Natural history and determinants of clinical severity of sickle cell disease
Abstract
Some of the factors determining the extremely variable clinical course of homozygous sickle cell disease are being identified. Genetic factors include alpha-thalassemia, beta-globin gene haplotypes, heterocellular hereditary persistence of fetal hemoglobin, and high total hemoglobin. Other factors include a variety of environmental variables and socioeconomic status. These risk factors, when occurring in conjunction with apparently random precipitating events, produce features of the disease. Many complications--which are age specific, with highest morbidity and mortality in the first 5 years--may be prevented by specific education and prophylaxis. Current median survival in individuals with sickle cell disease in the United States is approximately 40 to 50 years, at which age the major determinants of mortality are chronic end organ damage of the lungs and kidneys.
Similar articles
-
Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review.Am J Epidemiol. 2000 May 1;151(9):839-45. doi: 10.1093/oxfordjournals.aje.a010288. Am J Epidemiol. 2000. PMID: 10791557 Review.
-
Sickle cell anemia. Beta s gene cluster haplotypes as genetic markers for severe disease expression.Am J Dis Child. 1993 Nov;147(11):1197-202. doi: 10.1001/archpedi.1993.02160350071011. Am J Dis Child. 1993. PMID: 8237915 Review.
-
The natural history of sickle cell disease.Cold Spring Harb Perspect Med. 2013 Oct 1;3(10):a011783. doi: 10.1101/cshperspect.a011783. Cold Spring Harb Perspect Med. 2013. PMID: 23813607 Free PMC article. Review.
-
Molecular biology of hemoglobin: its application to sickle cell anemia and thalassemia.Schweiz Med Wochenschr Suppl. 1991;43:51-4. Schweiz Med Wochenschr Suppl. 1991. PMID: 1726857 Review.
-
Genetic Background of the Sickle Cell Disease Pediatric Population of Dakar, Senegal, and Characterization of a Novel Frameshift β-Thalassemia Mutation [HBB: c.265_266del; p.Leu89Glufs*2].Hemoglobin. 2017 Mar;41(2):89-95. doi: 10.1080/03630269.2017.1339610. Epub 2017 Jul 3. Hemoglobin. 2017. PMID: 28670947 Clinical Trial.
Cited by
-
Sickle cell disease in central India.Indian J Pediatr. 2004 Sep;71(9):789-93. doi: 10.1007/BF02730713. Indian J Pediatr. 2004. PMID: 15448384
-
Blood transfusions for treating acute chest syndrome in people with sickle cell disease.Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD007843. doi: 10.1002/14651858.CD007843.pub4. Cochrane Database Syst Rev. 2020. PMID: 31942751 Free PMC article.
-
Progressive vasoconstriction with sequential thermal stimulation indicates vascular dysautonomia in sickle cell disease.Blood. 2020 Sep 3;136(10):1191-1200. doi: 10.1182/blood.2020005045. Blood. 2020. PMID: 32518948 Free PMC article.
-
Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.Blood Cells Mol Dis. 2009 Jul-Aug;43(1):58-62. doi: 10.1016/j.bcmd.2009.02.006. Epub 2009 Apr 5. Blood Cells Mol Dis. 2009. PMID: 19346141 Free PMC article.
-
Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study.BMJ. 1999 Jun 12;318(7198):1585-90. doi: 10.1136/bmj.318.7198.1585. BMJ. 1999. PMID: 10364116 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical